GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » ROC (Joel Greenblatt) %

Entheon Biomedical (Entheon Biomedical) ROC (Joel Greenblatt) % : 0.00% (As of Nov. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Entheon Biomedical ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Entheon Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2023 was 0.00%.

The historical rank and industry rank for Entheon Biomedical's ROC (Joel Greenblatt) % or its related term are showing as below:

ENTBF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1762.88   Med: -512.46   Max: -13.33
Current: -82.11

During the past 7 years, Entheon Biomedical's highest ROC (Joel Greenblatt) % was -13.33%. The lowest was -1762.88%. And the median was -512.46%.

ENTBF's ROC (Joel Greenblatt) % is ranked better than
69.57% of 1469 companies
in the Biotechnology industry
Industry Median: -336.59 vs ENTBF: -82.11

Entheon Biomedical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Entheon Biomedical ROC (Joel Greenblatt) % Historical Data

The historical data trend for Entheon Biomedical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical ROC (Joel Greenblatt) % Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -46.61 -27.17 -1,870.39 -906.78 -

Entheon Biomedical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -236.18 - - - -

Competitive Comparison of Entheon Biomedical's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Entheon Biomedical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's ROC (Joel Greenblatt) % falls into.



Entheon Biomedical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Aug. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.021) - (0.031 + 0 + 0)
=-0.01

Working Capital(Q: Nov. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.033) - (0.062 + 0 + 0)
=-0.029

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Entheon Biomedical for the quarter that ended in Nov. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Nov. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2023  Q: Nov. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.22/( ( (0 + max(-0.01, 0)) + (0 + max(-0.029, 0)) )/ 1 )
=-0.22/( ( 0 + 0 )/ 1 )
=-0.22/0
= %

Note: The EBIT data used here is four times the quarterly (Nov. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (OTCPK:ENTBF) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Entheon Biomedical ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical (Entheon Biomedical) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.